<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1544">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345848</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00794</org_study_id>
    <nct_id>NCT04345848</nct_id>
  </id_info>
  <brief_title>Preventing COVID-19 Complications With Low- and High-dose Anticoagulation</brief_title>
  <acronym>COVID-HEP</acronym>
  <official_title>Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Multicentric Randomized, Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ongoing COVID-19 pandemic affects millions of humans worldwide and has led to thousands&#xD;
      of acute medical hospitalizations. There is evidence that hospitalized cases often suffer&#xD;
      from an important infection-related coagulopathy and from elevated risks of thrombosis.&#xD;
      Anticoagulants may have positive effects here, to reduce the burden of thrombotic disease and&#xD;
      the hyperactivity of coagulation, and may also hold beneficial anti-inflammatory effects&#xD;
      against sepsis and the development of ARDS.&#xD;
&#xD;
      The investigators hypothesize that high-dose anticoagulants, compared with low-dose&#xD;
      anticoagulants, lower the risk of venous and arterial thrombosis, disseminated intravascular&#xD;
      coagulation (DIC) and mortality. This open-label controlled trial will randomize hospitalized&#xD;
      adults with severe COVID-19 infection to therapeutic anticoagulation vs. thromboprophylaxis&#xD;
      during the hospital stay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of ischemic stroke, myocardial infarction and/or limb ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of symptomatic venous thromboembolism or asymptomatic proximal leg deep vein thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disseminated intravascular coagulation</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of DIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis-induced coagulopathy</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of SIC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress syndrome</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of ARDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durations of hospital stay, ICU stay, ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days with these care processes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment score</measure>
    <time_frame>30 days</time_frame>
    <description>Highest score per participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical deterioration</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of clinical deterioration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of ISTH-defined major bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically relevant non-major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of ISTH-defined CRNMB</description>
  </other_outcome>
  <other_outcome>
    <measure>Heparin-induced thrombocytopenia</measure>
    <time_frame>30 days</time_frame>
    <description>Risk of documented HIT</description>
  </other_outcome>
  <other_outcome>
    <measure>PaO2/FiO2 index</measure>
    <time_frame>30 days</time_frame>
    <description>Measures of PaO2/FiO2 among participants with mechanical ventilation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Therapeutic anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or intravenous unfractionated heparin, from admission until the end of hospital stay or clinical recovery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylactic anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be treated with prophylactic doses of subcutaneous low-molecular-weight heparin (enoxaparin) or unfractionated heparin, from admission until the end of hospital stay or clinical recovery. If hospitalized in the intensive care unit, they will receive an augmented thromboprophylaxis regimen as standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Two different doses of anticoagulation</description>
    <arm_group_label>Prophylactic anticoagulation</arm_group_label>
    <arm_group_label>Therapeutic anticoagulation</arm_group_label>
    <other_name>Unfractionated heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: adult patient with COVID-19 infections, admitted to:&#xD;
&#xD;
          -  an acute non-critical medical ward with admission D-dimer levels &gt;1,000ng/mL, or&#xD;
&#xD;
          -  an acute critical ward (ICU, intermediate care unit)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ongoing or planned therapeutic anticoagulation for any other indication&#xD;
&#xD;
          -  contra-indication to therapeutic anticoagulation&#xD;
&#xD;
          -  hypersensitivity to heparin&#xD;
&#xD;
          -  personal history of heparin-induced thrombocytopenia&#xD;
&#xD;
          -  suspected or confirmed bacterial endocarditis&#xD;
&#xD;
          -  bleeding events or tendency due to a suspected or confirmed hemostatic bleeding&#xD;
             disorder&#xD;
&#xD;
          -  organic lesion prone to bleeding&#xD;
&#xD;
          -  platelet count &lt;50G/L, Hb level &lt;80g/L&#xD;
&#xD;
          -  ongoing or recent (&lt;30 days) major bleeding, ischemic stroke, trauma, surgery&#xD;
&#xD;
          -  use of dual antiplatelet therapy&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  bodyweight &lt;40kg or &gt;150kg.&#xD;
&#xD;
          -  end of life care setting&#xD;
&#xD;
          -  unwillingness to consent&#xD;
&#xD;
          -  ongoing participation in a COVID-19 randomized clinical trial testing another&#xD;
             therapeutic intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Blondon</last_name>
      <phone>+41.22.372.92.92</phone>
      <email>marc.blondon@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mazzolai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Locarno</name>
      <address>
        <city>Locarno</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Stricker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital du Valais</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Manzocchi-Besson</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Marc Blondon</investigator_full_name>
    <investigator_title>Attending Physician, Angiology</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>heparin</keyword>
  <keyword>thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

